Convention Name to Start At present at 4:30 p.m. (ET)
- 3Q 2024 Whole revenues of $70M; +37% vs. 3Q 2023
- YTD 2024 Whole revenues of $209M; +49% vs. YTD 2023
- YTD 2024 Internet revenue of $20 million; Non-GAAP internet revenue of $45 million
- Orphan lung illness research continuing as deliberate
- MNKD-101 Part 3 medical trial expands globally
- MNKD-201 Part 1 efficiently accomplished; Plan to satisfy with FDA in 1H 2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) — MannKind Company MNKD right this moment reported monetary outcomes for the quarter ended September 30, 2024.
“Our enterprise demonstrated double-digit income development in comparison with final 12 months, led by Tyvaso DPI revenues,” mentioned Michael Castagna, PharmD, Chief Govt Officer of MannKind Company. “The third quarter has additionally been marked by sturdy progress in our medical improvement packages, with enrollment underway within the Part 3 trial of MNKD-101 to review its impact in NTM lung illness and profitable completion of a Part 1 trial of MNKD-201 for IPF. We additionally lately introduced optimistic topline outcomes from the Afrezza INHALE-3 post-marketing research and anticipate to announce topline knowledge from the Part-3 INHALE-1 pediatric research by year-end.”
Third Quarter 2024 Outcomes
Income Highlights
| Three Months Ended September 30, |
||||||||||||||||
| 2024 | 2023 | $ Change | % Change | |||||||||||||
| ({Dollars} in hundreds) | ||||||||||||||||
| Royalties – collaboration | $ | 27,083 | $ | 20,218 | $ | 6,865 | 34 | % | ||||||||
| Income – collaborations and companies | 23,268 | 13,108 | $ | 10,160 | 78 | % | ||||||||||
| Internet income – Afrezza | 15,035 | 13,476 | $ | 1,559 | 12 | % | ||||||||||
| Internet income – V-Go | 4,693 | 4,451 | $ | 242 | 5 | % | ||||||||||
| Whole revenues | $ | 70,079 | $ | 51,253 | $ | 18,826 | 37 | % | ||||||||
Within the third quarter of 2024, in comparison with the identical interval in 2023:
- royalties for Tyvaso DPI® elevated $6.9 million, or 34%, as a consequence of elevated gross sales by United Therapeutics (“UT”);
- collaborations and companies income elevated $10.2 million, or 78%, primarily attributable to a rise in manufacturing actions for Tyvaso DPI;
- Afrezza® internet income elevated $1.6 million, or 12%, on account of larger demand and improved gross-to-net changes; and
- V-Go® internet income elevated $0.2 million, or 5%, on account of improved gross-to-net changes and elevated value, partially offset by decrease product demand.
Business product gross margin within the third quarter of 2024 was 84% in comparison with 78% for a similar interval in 2023. The rise in gross margin was primarily attributable to a rise in Afrezza internet income.
Value of income – collaborations and companies for the third quarter of 2024 was $14.8 million in comparison with $10.3 million for a similar interval in 2023. The $4.5 million improve was primarily attributable to elevated manufacturing quantity for Tyvaso DPI.
Analysis and improvement (“R&D”) bills for the third quarter of 2024 had been $12.9 million in comparison with $10.0 million for a similar interval in 2023. The $2.9 million improve was primarily attributed to elevated prices for a Part 3 medical research of MNKD-101, a Part 1 medical research of a dry-powder formulation of MNKD-201, and personnel prices as a consequence of elevated headcount following a transaction with Pulmatrix, Inc.
Promoting bills had been $13.1 million for the third quarter of 2024 in comparison with $13.4 million for a similar interval in 2023. The $0.3 million lower was primarily as a consequence of diminished personnel prices associated to a gross sales pressure restructuring accomplished through the first quarter of 2024, partially offset by a rise in promotional actions.
Normal and administrative bills had been $10.8 million for the third quarter of 2024 in comparison with $10.5 million for a similar interval in 2023. The $0.3 million improve was primarily attributable to will increase in personnel prices partially offset by diminished consulting charges.
Curiosity revenue, internet, was $3.2 million for the third quarter of 2024 in comparison with $1.6 million for a similar interval in 2023. The $1.6 million improve was primarily as a consequence of a rise within the underlying investments from the proceeds of the sale of 1% of our Tyvaso DPI royalties in December 2023 and better yields on our securities portfolio.
Curiosity expense on legal responsibility on the market of future royalties was $4.1 million for the third quarter of 2024 and was attributable to imputed curiosity and amortization of debt issuance prices on the legal responsibility recorded in reference to the sale of 1% of our Tyvaso DPI royalties in December 2023.
Curiosity expense on financing legal responsibility associated to the sale-leaseback of our Danbury manufacturing facility was $2.5 million for the third quarter of 2024 and remained in keeping with the identical interval in 2023.
Curiosity expense was $1.8 million for the third quarter of 2024 in comparison with $2.8 million for a similar interval in 2023. The lower of $1.0 million was primarily as a consequence of compensation of the MidCap credit score facility and Mann Group convertible word in April 2024.
Achieve on discount buy of $5.3 million for the third quarter of 2024 was the results of the surplus of the honest worth of internet property acquired over the honest worth of the consideration paid within the Pulmatrix transaction.
9 Months September 30, 2024
Income Highlights
| 9 Months Ended September 30, |
||||||||||||||||
| 2024 | 2023 | $ Change | % Change | |||||||||||||
| ({Dollars} in hundreds) | ||||||||||||||||
| Royalties – collaboration | $ | 75,326 | $ | 50,951 | $ | 24,375 | 48 | % | ||||||||
| Income – collaborations and companies | 74,130 | 35,705 | $ | 38,425 | 108 | % | ||||||||||
| Internet income – Afrezza | 45,762 | 39,427 | $ | 6,335 | 16 | % | ||||||||||
| Internet income – V-Go | 13,510 | 14,407 | $ | (897 | ) | (6 | %) | |||||||||
| Whole revenues | $ | 208,728 | $ | 140,490 | $ | 68,238 | 49 | % | ||||||||
For the 9 months ended September 30, 2024, in comparison with the identical interval in 2023:
- royalties associated to Tyvaso DPI elevated $24.4 million, or 48%, as a consequence of elevated gross sales by UT;
- collaborations and companies income elevated $38.4 million, or 108%, primarily attributable to a rise in manufacturing actions for Tyvaso DPI;
- Afrezza internet income for the 9 months ended September 30, 2024 elevated $6.3 million, or 16%, primarily on account of larger demand and value and improved gross-to-net changes; and
- V-Go internet income for the 9 months ended September 30, 2024 decreased $0.9 million, or 6%, on account of decrease product demand, partially offset by improved gross-to-net changes and elevated value.
Business product gross margin within the 9 months ended September 30, 2024 was 79% in comparison with 73% for a similar interval in 2023. The rise in gross margin was primarily attributable to a rise in Afrezza internet income.
Value of income – collaborations and companies for the 9 months ended September 30, 2024 was $44.4 million in comparison with $30.0 million for a similar interval in 2023. The $14.4 million improve was primarily attributable to elevated manufacturing quantity for product offered to UT.
R&D bills for the 9 months ended September 30, 2024 had been $34.8 million in comparison with $22.0 million for a similar interval in 2023. The $12.8 million improve was primarily attributed to elevated expenditures for improvement actions and a Part 3 medical research of MNKD-101, a Part 1 research of MNKD-201, and personnel prices as a consequence of elevated headcount on account of the Pulmatrix transaction.
Promoting bills had been $36.2 million within the 9 months ended September 30, 2024 in comparison with $40.8 million for a similar interval in 2023. The $4.6 million lower was primarily as a consequence of diminished personnel prices associated to a gross sales pressure restructuring accomplished through the first quarter of 2024.
Normal and administrative bills for the 9 months ended September 30, 2024 had been $34.2 million in comparison with $33.0 million for a similar interval in 2023. The $1.2 million improve was primarily attributable to a lack of $1.4 million associated to estimated returns related to gross sales of V-Go that pre-date our acquisition of the product and will increase in personnel prices, partially offset by diminished consulting charges.
Curiosity revenue, internet, was $9.8 million for the 9 months ended September 30, 2024 in comparison with $4.4 million for a similar interval in 2023. The $5.4 million improve was primarily as a consequence of a rise within the underlying investments from the proceeds of the sale of 1% of our Tyvaso DPI royalties in December 2023 and better yields on our securities portfolio.
Curiosity expense on legal responsibility on the market of future royalties was $12.7 million for the 9 months ended September 30, 2024 and was attributable to imputed curiosity and amortization of debt issuance prices on the legal responsibility recorded in reference to the sale of 1% of our Tyvaso DPI royalties in December 2023.
Curiosity expense on financing legal responsibility associated to the sale-leaseback of our Danbury manufacturing facility was $7.4 million for the 9 months ended September 30, 2024 and remained in keeping with the identical interval in 2023.
Curiosity expense was $10.4 million for the 9 months ended September 30, 2024 in comparison with $12.5 million for a similar interval in 2023. The lower of $2.1 million was primarily as a consequence of compensation of the MidCap credit score facility and Mann Group convertible word in April 2024.
Achieve on discount buy of $5.3 million for the 9 months ended September 30, 2024 was the results of the surplus of the honest worth of internet property acquired over the honest worth of the consideration paid within the Pulmatrix transaction.
Loss on available-for-sale securities for the 9 months ended September 30, 2024 was $1.6 million ensuing from the modification of the Thirona word phrases. Achieve on available-for-sale securities for a similar interval in 2023 was $0.9 million on account of the change in honest worth of the Thirona funding.
Loss on extinguishment of debt of $7.1 million for the 9 months ended September 30, 2024 was incurred in reference to the prepayment of the MidCap credit score facility and the Mann Group convertible word in April 2024.
Money, money equivalents and investments as of September 30, 2024 had been $268.4 million.
Non-GAAP Measures
To complement our condensed consolidated monetary statements offered underneath U.S. usually accepted accounting ideas (“GAAP”), we’re presenting non-GAAP internet revenue (loss) and non-GAAP internet revenue (loss) per share – diluted, that are non-GAAP monetary measures. We’re offering these non-GAAP monetary measures to reveal further data to facilitate the comparability of previous and current operations, and they’re among the many indicators administration makes use of as a foundation for evaluating our monetary efficiency. We consider that these non-GAAP monetary measures, when thought of along with our GAAP monetary outcomes, present administration and traders with an extra understanding of our enterprise working outcomes, together with underlying tendencies.
These non-GAAP monetary measures aren’t meant to be thought of in isolation or as an alternative choice to comparable GAAP measures; must be learn at the side of our condensed consolidated monetary statements ready in accordance with GAAP; don’t have any standardized that means prescribed by GAAP; and aren’t ready underneath any complete set of accounting guidelines or ideas. As well as, sometimes sooner or later there could also be different objects that we could exclude for functions of our non-GAAP monetary measures; and we could sooner or later stop to exclude objects that we have now traditionally excluded for functions of our non-GAAP monetary measures. Likewise, we could decide to switch the character of changes to reach at our non-GAAP monetary measures. Due to the non-standardized definitions of non-GAAP monetary measures, the non-GAAP monetary measures as utilized by us on this report have limits of their usefulness to traders and could also be calculated in a different way from, and due to this fact might not be instantly similar to equally titled measures utilized by different corporations.
The next desk reconciles our monetary measures for internet revenue (loss) and internet revenue (loss) per share (“EPS”) for diluted weighted common shares as reported in our condensed consolidated statements of operations to a non-GAAP presentation.
| Three Months | 9 Months | ||||||||||||||||||||||||||||||
| Ended September 30, | Ended September 30, | ||||||||||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||||||||||
| Internet Earnings | Primary EPS | Internet Earnings | Primary EPS | Internet Earnings | Primary EPS | Internet Loss | Primary EPS | ||||||||||||||||||||||||
| (In hundreds besides per share knowledge) | |||||||||||||||||||||||||||||||
| GAAP reported internet revenue (loss) | $ | 11,550 | $ | 0.04 | $ | 1,721 | $ | 0.01 | $ | 20,166 | $ | 0.07 | $ | (13,339 | ) | $ | (0.05 | ) | |||||||||||||
| Non-GAAP changes: | |||||||||||||||||||||||||||||||
| Bought portion of royalty income(1) | (2,708 | ) | (0.01 | ) | — | — | (7,533 | ) | (0.03 | ) | — | — | |||||||||||||||||||
| Curiosity expense on legal responsibility on the market of future royalties | 4,089 | 0.02 | — | — | 12,720 | 0.04 | — | — | |||||||||||||||||||||||
| Inventory compensation | 5,227 | 0.02 | 4,601 | 0.02 | 15,540 | 0.06 | 13,836 | 0.05 | |||||||||||||||||||||||
| Loss (achieve) on international forex transaction | 2,454 | 0.01 | (2,065 | ) | (0.01 | ) | 526 | — | (860 | ) | — | ||||||||||||||||||||
| Achieve on discount buy | (5,259 | ) | (0.02 | ) | — | — | (5,259 | ) | (0.02 | ) | — | — | |||||||||||||||||||
| Loss on extinguishment of debt | — | — | — | — | 7,050 | 0.03 | — | — | |||||||||||||||||||||||
| Loss (achieve) on available-for-sale securities | — | — | — | — | 1,550 | 0.01 | (932 | ) | — | ||||||||||||||||||||||
| Non-GAAP adjusted internet revenue (loss) | $ | 15,353 | $ | 0.06 | $ | 4,257 | $ | 0.02 | $ | 44,760 | $ | 0.16 | $ | (1,295 | ) | $ | (0.00 | ) | |||||||||||||
| Weighted common shares used to compute internet revenue (loss) per share – primary | 274,998 | 268,732 | 272,811 | 266,126 | |||||||||||||||||||||||||||
__________________________
(1) Represents the non-cash portion of the 1% royalty on internet gross sales of Tyvaso DPI earned through the durations offered which is remitted to the royalty purchaser and acknowledged as royalties – collaboration in our consolidated statements of operations. Our revenues from royalties – collaboration throughout 3Q 2024 and the 9 months ended September 30, 2024 totaled $27.1 million and $75.3 million, respectively, of which $2.7 million and $7.5 million, respectively, had been attributed to the royalty purchaser.
Scientific Improvement Replace and Anticipated Milestones
Afrezza INHALE-3 (T1D, Afrezza vs. normal of care a number of each day injections or pumps) Part 4 medical trial
- High-level 30-week outcomes demonstrated that switching to or remaining on Afrezza allowed practically twice as many individuals to get to the A1C (<7%) aim through the extension interval
- Extra knowledge to be offered at Superior Applied sciences and Therapies for Diabetes (ATTD) and different conferences in 1H 2025
Afrezza INHALE-1 Pediatric Part 3 medical trial
- Major endpoint evaluation outcomes anticipated in 4Q 2024
- Six-month knowledge with security extension anticipated in 1H 2025
- FDA submission for label growth deliberate in 2025
MNKD-101 (Clofazimine Inhalation Suspension) Part 3 (ICoN-1) medical trial
- Trial cleared to proceed in 4 international locations (U.S., Japan, South Korea and Australia) with a fifth (Taiwan) anticipated in 4Q 2024
- First affected person randomized within the US in 3Q
- Roughly 230 members to be randomized at 100+ websites for at least 180 evaluable members
MNKD-201 (nintedanib DPI) Part 1 medical trial
- Trial efficiently accomplished, major goal met demonstrating optimistic security outcomes and was well-tolerated in wholesome volunteers
- Contributors didn’t expertise adversarial occasions sometimes reported with oral nintedanib
- Preclinical persistent toxicology didn’t present any adversarial findings
- FDA Finish-of-Part 1 assembly anticipated in 1H 2025
Convention Name
MannKind will host a convention name and presentation webcast to debate these outcomes right this moment at 4:30 p.m. Japanese Time. The webcast will likely be accessible through a hyperlink on MannKind’s web site. A replay can even be obtainable in the identical location inside 24 hours after the decision and accessible for roughly 90 days.
About MannKind
MannKind Company MNKD focuses on the event and commercialization of progressive inhaled therapeutic merchandise and gadgets to handle critical unmet medical wants for these residing with endocrine and orphan lung ailments.
We’re dedicated to utilizing our formulation capabilities and machine engineering prowess to reduce the burden of ailments reminiscent of diabetes, nontuberculous mycobacterial (NTM) lung illness, pulmonary fibrosis, and pulmonary hypertension. Our signature applied sciences – dry-powder formulations and inhalation gadgets – supply speedy and handy supply of medicines to the deep lung the place they will exert an impact domestically or enter the systemic circulation, relying on the goal indication.
With a passionate group of Mannitarians collaborating nationwide, we’re on a mission to offer individuals management of their well being and the liberty to dwell life.
Please go to mannkindcorp.com to study extra, and comply with us on LinkedIn, Facebook, X or Instagram.
Ahead-Trying Statements
Statements on this press launch that aren’t statements of historic truth are forward-looking statements that contain dangers and uncertainties. These statements embody, with out limitation, statements concerning the anticipated timing of affected person enrollment and world growth in a medical research of MNKD-101; the anticipated timing for knowledge read-outs from medical research of Afrezza; timing for an end-of-Part 1 assembly with the FDA for MNKD-201; and the timing of a deliberate FDA submission for Afrezza. Phrases reminiscent of “believes,” “anticipates,” “plans,” “expects,” “intend,” “will,” “aim,” “potential” and comparable expressions are meant to establish forward-looking statements. These forward-looking statements are based mostly upon MannKind’s present expectations. Precise outcomes and the timing of occasions might differ materially from these anticipated in such forward-looking statements on account of numerous dangers and uncertainties, which embody, with out limitation, dangers related to growing product candidates; dangers and uncertainties associated to unexpected delays which will affect the timing of medical trials and reporting knowledge; dangers related to security and different problems of our merchandise and product candidates; dangers related to the regulatory overview course of; and different dangers detailed in MannKind’s filings with the Securities and Change Fee (“SEC”), together with underneath the “Threat Components” heading of its Annual Report on Type 10-Okay for the 12 months ended December 31, 2023, filed with the SEC on February 27, 2024, and subsequent periodic studies on Type 10-Q. You’re cautioned to not place undue reliance on these forward-looking statements, which communicate solely as of the date of this press launch. All forward-looking statements are certified of their entirety by this cautionary assertion, and MannKind undertakes no obligation to revise or replace any forward-looking statements to mirror occasions or circumstances after the date of this press launch.
Tyvaso DPI is a trademark of United Therapeutics Company.
AFREZZA, MANNKIND, and V-GO are registered emblems of MannKind Company.
| MANNKIND CORPORATION AND SUBSIDIARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||||||||||
| Three Months Ended September 30, |
9 Months Ended September 30, |
|||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| (In hundreds besides per share knowledge) | ||||||||||||||||
| Revenues: | ||||||||||||||||
| Internet income – business product gross sales | $ | 19,728 | $ | 17,927 | $ | 59,272 | $ | 53,834 | ||||||||
| Income – collaborations and companies | 23,268 | 13,108 | 74,130 | 35,705 | ||||||||||||
| Royalties – collaboration | 27,083 | 20,218 | 75,326 | 50,951 | ||||||||||||
| Whole revenues | 70,079 | 51,253 | 208,728 | 140,490 | ||||||||||||
| Bills: | ||||||||||||||||
| Value of products offered | 3,197 | 3,995 | 12,621 | 14,749 | ||||||||||||
| Value of income – collaborations and companies | 14,826 | 10,259 | 44,377 | 29,955 | ||||||||||||
| Analysis and improvement | 12,926 | 9,989 | 34,755 | 22,047 | ||||||||||||
| Promoting | 13,093 | 13,440 | 36,189 | 40,752 | ||||||||||||
| Normal and administrative | 10,823 | 10,538 | 34,168 | 33,027 | ||||||||||||
| Loss (achieve) on international forex transaction | 2,454 | (2,065 | ) | 526 | (860 | ) | ||||||||||
| Whole bills | 57,319 | 46,156 | 162,636 | 139,670 | ||||||||||||
| Earnings from operations | 12,760 | 5,097 | 46,092 | 820 | ||||||||||||
| Different revenue (expense): | ||||||||||||||||
| Curiosity revenue, internet | 3,179 | 1,580 | 9,790 | 4,429 | ||||||||||||
| Curiosity expense on legal responsibility on the market of future royalties | (4,089 | ) | — | (12,720 | ) | — | ||||||||||
| Curiosity expense on financing legal responsibility | (2,470 | ) | (2,459 | ) | (7,361 | ) | (7,332 | ) | ||||||||
| Curiosity expense | (1,801 | ) | (2,815 | ) | (10,419 | ) | (12,474 | ) | ||||||||
| Achieve on discount buy | 5,259 | — | 5,259 | — | ||||||||||||
| Different revenue | 32 | 318 | 32 | 286 | ||||||||||||
| Loss on extinguishment of debt | — | — | (7,050 | ) | — | |||||||||||
| (Loss) achieve on available-for-sale securities | — | — | (1,550 | ) | 932 | |||||||||||
| Whole different expense | 110 | (3,376 | ) | (24,019 | ) | (14,159 | ) | |||||||||
| Earnings (loss) earlier than revenue tax expense | 12,870 | 1,721 | 22,073 | (13,339 | ) | |||||||||||
| Earnings tax expense | 1,320 | — | 1,907 | — | ||||||||||||
| Internet revenue (loss) | $ | 11,550 | $ | 1,721 | $ | 20,166 | $ | (13,339 | ) | |||||||
| Internet revenue (loss) per share – primary | $ | 0.04 | $ | 0.01 | $ | 0.07 | $ | (0.05 | ) | |||||||
| Weighted common shares used to compute internet revenue (loss) per share – primary | 274,998 | 268,732 | 272,811 | 266,126 | ||||||||||||
| Internet revenue (loss) per share – diluted | $ | 0.04 | $ | 0.01 | $ | 0.07 | $ | (0.05 | ) | |||||||
| Weighted common shares used to compute internet revenue (loss) per share – diluted | 284,693 | (1) | 323,770 | (1) | 281,407 | (1) | 266,126 | |||||||||
__________________________
(1) Diluted weighted common shares (“DWAS”) differs from primary as a result of weighted common variety of shares that will be excellent upon train or vesting of excellent share-based funds to workers and conversion of convertible notes. For the three and 9 months ended September 30, 2024 DWAS included and 9,695 and eight,596, respectively, shares of excellent share-based funds. 44,120 shares issuable upon conversion of our Senior convertible notes had been excluded as their impact can be antidilutive. For the three months ended September 30, 2023 DWAS included 7,548 shares of excellent share-based funds, 44,120 shares issuable upon conversion of our Senior convertible notes, and three,370 shares issuable upon conversion of our Mann Group convertible word.
| MANNKIND CORPORATION AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||||
| September 30, 2024 | December 31, 2023 | |||||||
| (In hundreds besides share and per share knowledge) |
||||||||
| ASSETS | ||||||||
| Present property: | ||||||||
| Money and money equivalents | $ | 62,373 | $ | 238,480 | ||||
| Quick-term investments | 189,215 | 56,619 | ||||||
| Accounts receivable, internet | 18,184 | 14,901 | ||||||
| Stock | 26,663 | 28,545 | ||||||
| Pay as you go bills and different present property | 31,229 | 34,848 | ||||||
| Whole present property | 327,664 | 373,393 | ||||||
| Restricted money | 735 | — | ||||||
| Lengthy-term investments | 16,796 | 7,155 | ||||||
| Property and gear, internet | 85,339 | 84,220 | ||||||
| Goodwill | 1,931 | 1,931 | ||||||
| Different intangible property | 5,313 | 1,073 | ||||||
| Different property | 26,422 | 7,426 | ||||||
| Whole property | $ | 464,200 | $ | 475,198 | ||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||
| Present liabilities: | ||||||||
| Accounts payable | $ | 6,444 | $ | 9,580 | ||||
| Accrued bills and different present liabilities | 37,386 | 42,036 | ||||||
| Legal responsibility on the market of future royalties – present | 11,755 | 9,756 | ||||||
| Financing legal responsibility – present | 9,998 | 9,809 | ||||||
| Deferred income – present | 6,518 | 9,085 | ||||||
| Acknowledged loss on buy commitments – present | — | 3,859 | ||||||
| Midcap credit score facility – present | — | 20,000 | ||||||
| Whole present liabilities | 72,101 | 104,125 | ||||||
| Senior convertible notes | 227,941 | 226,851 | ||||||
| Legal responsibility on the market of future royalties – long run | 137,140 | 136,054 | ||||||
| Financing legal responsibility – long run | 94,005 | 94,319 | ||||||
| Deferred income – long run | 65,150 | 69,794 | ||||||
| Acknowledged loss on buy commitments – long run | 62,638 | 60,942 | ||||||
| Working lease legal responsibility | 12,167 | 3,925 | ||||||
| Milestone liabilities | 2,813 | 3,452 | ||||||
| Financing lease legal responsibility | 171 | — | ||||||
| Midcap credit score facility – long run | — | 13,019 | ||||||
| Mann Group convertible word | — | 8,829 | ||||||
| Accrued curiosity – Mann Group convertible word | — | 56 | ||||||
| Whole liabilities | 674,126 | 721,366 | ||||||
| Stockholders’ deficit: | ||||||||
| Undesignated most popular inventory, $0.01 par worth – 10,000,000 shares licensed; no shares issued or excellent as of September 30, 2024 or December 31, 2023 | — | — | ||||||
| Widespread inventory, $0.01 par worth – 800,000,000 shares licensed; 275,775,038 and 270,034,495 shares issued and excellent as of September 30, 2024 and December 31, 2023, respectively | 2,753 | 2,700 | ||||||
| Extra paid-in capital | 2,995,974 | 2,980,539 | ||||||
| Amassed different complete revenue | 588 | — | ||||||
| Amassed deficit | (3,209,241 | ) | (3,229,407 | ) | ||||
| Whole stockholders’ deficit | (209,926 | ) | (246,168 | ) | ||||
| Whole liabilities and stockholders’ deficit | $ | 464,200 | $ | 475,198 | ||||
MannKind Contacts: Investor Relations Ana Kapor (818) 661-5000 Electronic mail: [email protected] Media Relations Christie Iacangelo (818) 292-3500 Electronic mail: [email protected]
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
